M L Schweitzer1, B Stengel2, K Legrand1,3, S Briançon3, C Jacquelinet2,4, C Combe5,6, D Fouque7, Z A Massy2,8, M Laville7, L Frimat9, C Ayav10. 1. INSERM, CHU Nancy, Université de Lorraine, CIC-1433, Epidémiologie clinique, 54000, Nancy, France. 2. CESP Centre for Research in Epidemiology and population Health, UMRS 1018, University Paris-Saclay, University Paris Sud, UVSQ, 94807, Villejuif, France. 3. Université de lorraine, 4360 APEMAC, 54000, Nancy, EA, France. 4. Agence de la Biomédecine, Saint-Denis, France. 5. Service de Néphrologie Transplantation Dialyse Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. 6. Inserm, U1026, Université Bordeaux Segalen, Bordeaux, France. 7. Nephrology Department, Centre Hospitalier Lyon-Sud, Univ Lyon, UCBL, Carmen, 69495, Pierre-Bénite, France. 8. Nephrology Department, CHU Ambroise Paré, Boulogne, France. 9. Nephrology Department, CHU Nancy, Vandoeuvre-lès-Nancy, France. 10. INSERM, CHU Nancy, Université de Lorraine, CIC-1433, Epidémiologie clinique, 54000, Nancy, France. c.ayav@chru-nancy.fr.
Abstract
PURPOSE: To evaluate the association between obesity phenotypes and health-related quality of life (HRQoL) in non-dialysis-dependent CKD patients. METHODS: Data from the national CKD-REIN cohort which included 3033 patients with stage 3-4 CKD were used. Patients were divided into three groups: non-obese (NO) patients (BMI < 30 kg/m2), metabolically healthy obese (MHO) (BMI ≥ 30 kg/m2 and ≤ 1 criterion NCEP/ATP III), and metabolically unhealthy obese (MUO) (BMI ≥ 30 kg/m2 and ≥ 2 criteria NCEP/ATP III). HRQoL was measured by the KDQOL-36™ which comprised three disease-specific dimensions: symptoms, effects, and burden and two summaries scores: physical (PCS) and mental (MCS). We used a mixed effect model with adjustment on sociodemographic characteristics and comorbidities. RESULTS: A total of 2693 patients completed the self-administered questionnaires. MHO patients accounted for 3.4% of the cohort and for 12% of obese patients. In the NO group, average HRQoL scores were 77.2 ± 15.9 for symptoms, 83.5 ± 16.5 for effects, 76.8 ± 22.7 for burden, 43.5 ± 9.7 for PCS, and 47.9 ± 7.0 for MCS. In the multivariate analysis, scores were similar in MHO and NO patients, but significantly different with those in MUO patients: symptoms (- 0.7; p = 0.71 vs. - 3.0; p = 0.0025), effects (+ 1.2; p = 0.57 vs. - 4.3; p < 0.0001), burden (+ 2.7; p = 0.31 vs. - 3.6; p = 0.0031), and PCS (- 0.6; p = 0.58 vs. - 4.3; p < 0.0001). MCS was not associated with obesity phenotypes. CONCLUSIONS: This study demonstrated an association between obesity phenotypes and QoL in non-dialysis-dependent CKD patients. MUO patients had worse QoL than NO and MHO patients even after adjustment on comorbidities.
PURPOSE: To evaluate the association between obesity phenotypes and health-related quality of life (HRQoL) in non-dialysis-dependent CKD patients. METHODS: Data from the national CKD-REIN cohort which included 3033 patients with stage 3-4 CKD were used. Patients were divided into three groups: non-obese (NO) patients (BMI < 30 kg/m2), metabolically healthy obese (MHO) (BMI ≥ 30 kg/m2 and ≤ 1 criterion NCEP/ATP III), and metabolically unhealthy obese (MUO) (BMI ≥ 30 kg/m2 and ≥ 2 criteria NCEP/ATP III). HRQoL was measured by the KDQOL-36™ which comprised three disease-specific dimensions: symptoms, effects, and burden and two summaries scores: physical (PCS) and mental (MCS). We used a mixed effect model with adjustment on sociodemographic characteristics and comorbidities. RESULTS: A total of 2693 patients completed the self-administered questionnaires. MHO patients accounted for 3.4% of the cohort and for 12% of obesepatients. In the NO group, average HRQoL scores were 77.2 ± 15.9 for symptoms, 83.5 ± 16.5 for effects, 76.8 ± 22.7 for burden, 43.5 ± 9.7 for PCS, and 47.9 ± 7.0 for MCS. In the multivariate analysis, scores were similar in MHO and NO patients, but significantly different with those in MUO patients: symptoms (- 0.7; p = 0.71 vs. - 3.0; p = 0.0025), effects (+ 1.2; p = 0.57 vs. - 4.3; p < 0.0001), burden (+ 2.7; p = 0.31 vs. - 3.6; p = 0.0031), and PCS (- 0.6; p = 0.58 vs. - 4.3; p < 0.0001). MCS was not associated with obesity phenotypes. CONCLUSIONS: This study demonstrated an association between obesity phenotypes and QoL in non-dialysis-dependent CKD patients. MUO patients had worse QoL than NO and MHO patients even after adjustment on comorbidities.
Entities:
Keywords:
Chronic kidney disease; Metabolically healthy obesity; Obesity; Patient-reported outcomes; Quality of life
Authors: Isabella Busa; José M Ordóñez-Mena; Yaling Yang; Jane Wolstenholme; Stavros Petrou; Clare J Taylor; Chris A O'Callaghan; Simon D S Fraser; Maarten W Taal; Richard J McManus; Jennifer A Hirst; F D Richard Hobbs Journal: PLoS One Date: 2022-10-14 Impact factor: 3.752
Authors: Sang Heon Suh; Hong Sang Choi; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Dae Ho Lee; Soo Wan Kim Journal: Sci Rep Date: 2020-02-11 Impact factor: 4.379